arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Journey Medical Corp

DERM
$6.33 ▼ -0.18 (-2.84%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Journey Medical Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $174.0M
Dividend Yield —
Revenue Growth 23.3% ↗
Op. Margin 2.5% ↗
ROIC 0.8% ↗
FCF / Share $-0.06 ↘
Trailing P/E —
Price / Book 5.4x
FCF Yield —
Debt / Equity 0.79
info Valuation on last close. End-of-day price, Sep 24, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$18.51M
↑ +23.3% —
Net Income Profit after all expenses
$-312.00K
↑ +91.8% —
Operating Margin Operating profit as % of sales
2.5%
↑ +126.4% 13th
FCF / Share Free cash flow per share
$-0.06
↓ -159.2% —
Long-Term Debt Long-term obligations
$25.47M
— +0.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
11
Returns ↑
21
Financial Health →
39
Cash Quality ↑
69

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 7 years · 26 quarters